Главная страница
Навигация по странице:

  • Использованные источники

  • ззз. О. В. Гриднев Дорохова Евгения Николаевна


    Скачать 3.54 Mb.
    НазваниеО. В. Гриднев Дорохова Евгения Николаевна
    Дата05.03.2022
    Размер3.54 Mb.
    Формат файлаpdf
    Имя файлаvrem_rek.pdf
    ТипДокументы
    #383922
    страница18 из 26
    1   ...   14   15   16   17   18   19   20   21   ...   26
    Часть I
    Строка «а» Болезнь или состояние, непосредственно приведшее к смерти;
    Строка «б» Патологическое состояние, которое привело к возникновению вышеуказанной причины (при наличии);
    Строка «в» или «б», если последняя не была заполнена - Первоначальная причина смерти;
    Строка «г» Внешняя причина при травмах и отравлениях (при наличии);
    Часть II. Прочие важные состояния, способствовавшие смерти, но не связанные с болезнью или патологическим состоянием (при наличии); г) После завершения патологоанатомического или судебно-медицинского исследования заполняется раздел «заключительный патологоанатомический (судебно- медицинский) диагноз»
    • Скан-копия медицинского свидетельства о смерти.

    155
    Версия 13.1 (09.11.2021)
    • Основное заболевание;
    • Коморбидные, конкурирующие, сочетанные и фоновые заболевания;
    • Осложнения (основного заболевания, коморбиных заболеваний) – при их наличии;
    • Сопутствующие заболевания (при наличии).
    • Скан-копия второй части протокола патологоанатомического исследования или выписка из результатов дополнительных лабораторных исследований в случае проведения судебно-медицинского исследования; д) При внесении изменений в первое (предварительное или окончательное)
    «Медицинское свидетельство о смерти» (при необходимости в случае оформления повторного свидетельства взамен предварительного или окончательного), приложить скан-копию повторного медицинского свидетельства о смерти.
    Для получения доступа к информационному ресурсу необходимо направить заявку на предоставление доступа по форме, приведенной в инструкции на адрес электронной почты egisz@rt-eu.ru

    156
    Версия 13.1 (09.11.2021)
    Использованные источники
    1.
    Abramowicz J.S., Basseal J. Заявление о позиции WFUMB: как безопасно проводить ультразвуковое исследование и обеззараживать ультразвуковое оборудование в условиях
    COVID-19 // Ультразвуковая и функциональная диагностика. 2020. № 1. С. 12–23. Doi:
    10.24835/1607-0771-2020-1-12-23.
    Опубликовано до печати.
    Режим доступа:
    // http://www.rasudm.org/files/WFUMB-Position-Statement-COVID.pdf, свободный. Загл. с экрана.
    16.04.2020.
    2.
    Ai T. et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in
    China: A Report of 1014 Cases [published online ahead of print, 2020 Feb 26] // Radiology. 2020. 200642.
    Doi: 10.1148/radiol.2020200642.
    3.
    Al-Tawfiq J. A., Memish Z. A. Update on therapeutic options for Middle East Respiratory Syndrome
    Coronavirus (MERS-CoV) // Expert review of anti-infective therapy. 2017. 15. № 3. С. 269–275.
    4.
    Alserehi H. et al. Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome // BMC Infect Dis. 2016. №16, p. 105 5.
    Assiri A. et al. Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia // Clin Infect Dis. 2016. № 63. pp. 951-953 6.
    Baig A.M. et al..Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus
    Interaction, and
    Proposed
    Neurotropic
    Mechanisms.
    ACS
    Chem.
    Neurosci.
    2020. doi:10.1021/acschemneuro.0c00122.
    7.
    Bassetti M. The Novel Chinese Coronavirus (2019‐nCoV) Infections: challenges for fighting the storm https://doi.org/10.1111/eci.13209 URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13209 8.
    Behzadi M.A., Leyva-Grado V.H. Overview of Current Therapeutics and Novel Candidates Against
    Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections //
    Frontiers in microbiology. 2019. № 10. p. 1327.
    9.
    Beloncle F, Mercat A Approaches and Techniques to Avoid Development or Progression of Acute
    Respiratory Distress Syndrome Review Curr Opin Crit Care 2018 Feb;24(1):10-15. doi:
    10.1097/MCC.0000000000000477.
    10.
    Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts [published online ahead of print, 2020 Apr 15] //
    Ultraschall Med. 2020;10.1055/a-1149-9872. Doi: 10.1055/a-1149-9872.
    11.
    Bernheim A. et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. 2020:200463. doi:10.1148/radiol.2020200463.
    12.
    Canada.ca. 2019 novel coronavirus: Symptoms and treatment The official website of the Government of
    Canada
    URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel- coronavirusinfection/symptoms.html
    13.
    Carmeli Y. et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa.
    Arch Intern Med. 1999 May 24;159(10):1127-32.
    14.
    CDC. 2019 Novel Coronavirus URL: https://www.cdc.gov/coronavirus/2019-ncov/index.html
    15.
    Chaolin H. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China?
    Lancet 2020; 395: 497–506 Published Online January 24, 2020 https://doi.org/10.1016/ S0140-
    6736(20)30183-5 16.
    Chaomin Wu et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in
    Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.099 17.
    Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. doi: 10.1016/S0140-6736(20)30211-7 18.
    China CDC. Diagnosis and treatment protocolfor COVID-19 patients (trial version 7, revised)
    19.
    Chong Y.P. et al. Antiviral Treatment Guidelines for Middle East Respiratory Syndrome // Infection & chemotherapy. 2015. 47. № 3. pp. 212–222.
    20.
    Chung M. et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) // Radiology. 2020. V.
    295. No. 1. P. 202–207. Doi: 10.1148/radiol.2020200230.
    21.
    Cinatl J. et al. Treatment of SARS with human interferons // Lancet. 2003. 362. № 9380. pp. 293–294.
    22.
    Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: Interim Guidance. Updated 2 July 2015.
    WHO/MERS/Clinical/15.1 23.
    Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 International Journal of Antimicrobial Agents 2020.
    24.
    Commonwealth of Australia | Department of Health. Novel coronavirus (2019-nCoV) URL: https://www.health.gov.au/health-topics/novel-coronavirus-2019-ncov
    25.
    Corman V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
    //Eurosurveillance. 2020. (3)25. doi: 10.2807/1560-7917.ES

    157
    Версия 13.1 (09.11.2021)
    26.
    Coronavirus.
    URL
    :https://multimedia.scmp.com/widgets/china/wuhanvirus/?fbclid=IwAR2hDHzpZEh5Nj360i2O%201E
    S 78rXRFymAaFaUK6ZG4m0UTCV1xozulxX1jio
    COVID Care Protocol.
    Last Updated 05-11-2020 3:15 p.m.
    https://www.evms.edu/covid-19/covid_care_for_clinicians/#covidcare
    27.
    Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care .
    28.
    Critical Care COVID-19 Management Protocol (updated 4-15-2020).
    29.
    Dayer M.R. et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular
    Docking Study // Arch Clin Infect Dis. 2017 ; 12(4):e13823. doi: 10.5812/archcid.13823 30.
    Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi:
    10.1016/j.ijantimicag.2020.105938.
    31.
    Dyall J. et al. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current
    Therapeutic Options and Potential Targets for Novel Therapies // Drugs. 2017. 77. № 18. С. 1935–1966.
    32.
    European Commission. Novel coronavirus 2019-nCoV URL: https://ec.europa.eu/health/coronavirus_en
    33.
    Fan HH. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a
    2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2020 Mar 6. doi:
    10.1097/CM9.0000000000000797 34.
    Fang Y. et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR [published online ahead of print, 2020 Feb 19] // Radiology. 2020. 200432. Doi: 10.1148/radiol.2020200432.
    35.
    FDA. Novel coronavirus (2019-nCoV) URL: https://www.fda.gov/emergency-preparedness- andresponse/mcm-issues/novel-coronavirus-2019-ncov
    36.
    Federal
    Ministry of
    Health.
    Current information on the coronavirus
    URL: https://www.bundesgesundheitsministerium.de/en/en/press/2020/coronavirus.html
    37.
    Franquet T. Imaging of pulmonary viral pneumonia // Radiology. 2011. V. 260. No. 1. P. 18–39. Doi:
    10.1148/radiol.11092149.
    38.
    Gao, J., Tian, Z., & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 2020.
    39.
    Gautret F., Lagier J-C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an openlabel non-randomized clinical trial. International Journal of Antimicrobial Agents. In
    Press 17 March 2020 –DOI : 10.1016/j.ijantimicag.2020.105949 40.
    Gorbalenya A.E.et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses
    – a statement of the Coronavirus Study Group, 2020. doi: https://doi.org/10.1101/2020.02.07.937862 41.
    Halyabar O. et al.
    Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome,
    Pediatric
    Rheumatology, https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-019-0309-6 42.
    Hart B.J. et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays // The Journal of general virology. 2014. 95. Pt 3. С. 571–577.
    43.
    Henderson L.A. et al. On the Alert for Cytokine Storm: Immunopathology in COVID‐19 Arthritis &
    Rheumatology Vol. 0, No. 0, Month 2020, pp 1–5 DOI 10.1002/art.41285 44. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4a3c02bc-a256-48f2-90a8-
    14b48b7d197c&t=
    45. https://www.vmeda.org/wp-content/uploads/2020/03/koronavirus-metod-rekomendaczii.pdf
    46.
    Huang C. et al. Cinical features of patients infected with 2019 novel coronavirus in Wuhan, China //
    Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5. [Epub ahead of print]
    47.
    Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with
    COVID-19
    . Published by IDSA, https://www.idsociety.org/practice-guideline/covid-19-guideline- treatment-and-management/ , [COVID-19 Guideline, Part 1: Treatment and Management]
    48.
    Inui S. et al. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus
    Disease
    2019
    (COVID-19).
    Radiology:
    Cardiothoracic
    Imaging.
    2020;2:e200110. doi:10.1148/ryct.2020200110.
    49.
    Jeong S.Y. et al. MERS-CoV Infection in a Pregnant Woman in Korea. J Korean Med Sci. 2017
    Oct;32(10):1717-1720. doi: 10.3346/jkms.2017.32.10.1717.
    50.
    Jesú V. et al. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress
    Syndrome Caused by Coronavirus Disease 2019. ritical Care Explorations: April 2020 - Volume 2 - Issue
    4 - p e0111 doi: 10.1097/CCE.0000000000000111 51.
    Ji W. et al. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross‐species transmission from snake to human //Journal of Medical Virology. – 2020.
    52.
    Junqiang L. et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia https://doi.org/10.1148/radiol.2020200236 URL: https://pubs.rsna.org/doi/10.1148/radiol.2020200236

    158
    Версия 13.1 (09.11.2021)
    53.
    Kligerman S.J., Franks T.J., Galvin J.R. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia // Radiographics. 2013. V. 33. No. 7. P. 1951–1975. Doi: 10.1148/rg.337130057.
    54.
    Kumar B. et al. A Personalized Diagnostic and Treatment Approach for Macrophage Activation
    Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. Journal of Clinical
    Immunology, volume 37, pages 638–643(2017), https://link.springer.com/article/10.1007/s10875-017-
    0439-x
    55.
    Le Chang et al. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine
    Reviews 2020. doi:10.1016/j.tmrv.2020.02.003.
    56.
    Lee Kyung Soo. Pneumonia Associated with 2019 Novel Coronavirus: Can Computed Tomographic
    Findings Help Predict the Prognosis of the Disease? Korean Journal of Radiology(2020), 21 (3):257 57.
    Li Q et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia N
    Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316 58.
    Li X et al. Potential of large 'first generation' human-to-human transmission of 2019-nCoV. J Med Virol.
    2020 Jan 30. doi: 10.1002/jmv.25693. [Epub ahead of print]
    59.
    Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020 Jan 28. doi: 10.5582/bst.2020.01020. [Epub ahead of print]
    60.
    Lu W., Zhang S., Chen B. et al. A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound [published online ahead of print, 2020
    Apr 15] // Ultraschall Med. 2020;10.1055/a-1154-8795. Doi: 10.1055/a-1154-8795.
    61.
    Ludvigsson JF. Systematic review of COVID‐19 in children show milder cases and a better prognosis than adults https://doi.org/10.1111/apa.15270 62.
    Lupia T., Scabini S., Pinna S.M., Di Perri G., De Rosa F.G., Corcione S. 2019 novel coronavirus (2019- nCoV) outbreak: A new challenge, Journal of Global Antimicrobial Resistance 21 (2020) 22–27 63.
    Mandell L.A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults //Clinical infectious diseases.
    – 2007. – Т. 44. – №. Supplement_2. – pp. S27-S72.
    64.
    Mao L. et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A retrospective case series study; 2020. doi: https://doi.org/10.1101/2020.02.22.20026500 65.
    Maude S.L. et al. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging
    Therapies Cancer J. 2014 Mar-Apr; 20(2): 119–122. doi: 10.1097/PPO.0000000000000035 66.
    Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020
    Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
    67.
    Ministère des
    Solidarités et de la
    Santé
    Coronavirus: questions-réponses
    URL: https://solidaritessante.gouv.fr/soins-et-maladies/maladies/maladies- infectieuses/coronavirus/coronavirus-questionsreponses
    68.
    Mo Y., Fisher D.A. review of treatment modalities for Middle East Respiratory Syndrome // The Journal of antimicrobial chemotherapy. 2016. 71. № 12. pp. 3340–3350.
    69.
    Momattin H. et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)- possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013 Oct;17(10):e7928 70.
    National Health Commission of the People's Republic of China. URL: http://en.nhc.gov.cn
    71.
    Netland J. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the
    Absence of Encephalitis in Mice Transgenic for Human ACE2. J Virol. 2008;82:7264–75. doi:10.1128/JVI.00737-08.
    72.
    NHS. Coronavirus (2019-nCoV) URL: https://www.nhs.uk/conditions/wuhan-novel-coronavirus/
    73.
    Omrani A.S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study //The Lancet Infectious Diseases. 2014. Т. 14. №. 11. pp. 1090-1095.
    74.
    Outbreak of acute respiratory syndrome associated with a novel coronavirus, China: first local transmission in the
    EU/EEA
    − third update
    URL: https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-risk-assessment-china-
    31january-2020_0.pdf
    75.
    Pan F. et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus
    (COVID-19) Pneumonia [published online ahead of print, 2020 Feb 13] // Radiology. 2020. 200370. Doi:
    10.1148/radiol.2020200370.
    76.
    Park M.H. et al. Emergency cesarean section in an epidemic of the Middle East respiratory syndrome: a case report Korean J Anesthesiol, 69 (2016), pp. 287-291, doi: 10.4097/kjae.2016.69.3.287 77.
    Paul La Rosée et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood (2019) 133 (23): 2465–2477. https://doi.org/10.1182/blood.2018894618 78.
    Phan L. T. et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam
    //New England Journal of Medicine. – 2020.

    159
    Версия 13.1 (09.11.2021)
    79.
    Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV). URL: https://nextstrain.org/groups/blab/sars-like-cov
    80.
    Pogue J., Kaye K., Veve M., et al. "Real World" treatment of multi-drug resistant (MDR) or extensively- drug resistant (XDR) P. aeruginosa infections with ceftolozane/tazobactam (C/T) versus a polymyxin or aminoglycoside (Poly/AG) based regimen: a multicenter comparative effectiveness study. Proceedings of the IDweek 2018, October 3-7, San Francisco, USA. Poster/Abstract 2406.
    81.
    Public Health England. Investigation and initial clinical management of possible cases of novel coronavirus (2019-nCoV) infection URL: https://www.gov.uk/government/publications/wuhan- novelcoronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management- ofpossible-cases-of-wuhan-novel-coronavirus-wn-cov-infection
    82.
    Revel M.-P., Parkar A.P., Prosch H. et al. COVID-19 patients and the Radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI) //
    Eur. Radio. Accepted on April 2, 2020.
    83.
    Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J.Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi:
    10.1016/S0140-6736(20)30304-4.
    84.
    Rodriguez-Morales A. et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease, Volume 34, March–April 2020, 101623 https://doi.org/10.1016/j.tmaid.2020.101623 85.
    Royal Pharmaceutical Society of Great Britain Trading as Royal Pharmaceutical Society. Wuhan novel coronavirus URL: https://www.rpharms.com/resources/pharmacy-guides/wuhan-novel-coronavirus
    86.
    Rubin G.D., Ryerson C.J., Haramati L.B. et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society [published online ahead of print, 2020 Apr 7] // Radiology. 2020;201365. Doi: 10.1148/radiol.2020201365.
    87.
    Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M,Mansouri D. JAK
    Inhibition as a New Treatment Strategy for Patients with COVID-19. Int Arch Allergy Immunol. 2020
    May 11:1-9. doi: 10.1159/000508247.
    88.
    Shannon L. Maude et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N
    Engl J Med 2014;371:1507-17. DOI: 10.1056/NEJMoa1407222 89.
    Simone S. et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-
    CoV-2 respiratory infection. European Heart Journal, Volume 41, Issue 19, 14 May 2020, Pages 1861–
    1862, https://doi.org/10.1093/eurheartj/ehaa286 90.
    Soldati G., Smargiassi A., Inchingolo R. et al. Proposal for International Standardization of the Use of
    Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative, Reproducible Method [published online ahead of print, 2020 Mar 30] // J. Ultrasound Med. 2020;10.1002/jum.15285. Doi:
    10.1002/jum.15285.
    91.
    Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol. 2020 May 8;5(47). piieabc5367. doi:
    10.1126/sciimmunol.abc5367.
    92.
    Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar
    27. doi: 10.1111/jth.14817.
    93.
    The Centers for Disease Control and Prevention (CDC). Interim guidance for healthcare professionals on human infections with
    2019 novel coronavirus
    (2019-nCoV).
    URL: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html
    94.
    The State Council The People's Republic Of China URL: http://english.www.gov.cn/
    95.
    Touret, F., de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Research, 104762.
    96.
    Upchurch C.P. et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes //Chest. – 2018. – Т. 153. – №. 3. – pp. 601-610.
    97.
    Villar J,,et al.; Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 Feb 7.
    98.
    Wang L C-reactive Protein Levels in the Early Stage of COVID-19 Med Mal Infect. 2020 Mar 31;S0399-
    077X(20)30086-X. doi: 10.1016/j.medmal.2020.03.007. Online ahead of print
    99.
    Wang Z. et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends
    2020. doi:10.5582/bst.2020.01030.
    100. World Health Organization. COVID-19 Clinical management: living guidance. 25 January 2021.
    https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 101. World Health Organization. Infection prevention and control guidance for long-term care facilities in the context of COVID-19: interim guidance, 21 March 2020. World Health Organization; 2020.
    102. World Health Organization. Managing Ethical Issues in Infectious Disease Outbreaks. Publication date:
    2016. URL: https://www.who.int/ethics/publications/infectious-disease-outbreaks/en/

    160
    Версия 13.1 (09.11.2021)
    103. World Health Organization. WHO Blood Regulators Network (BRN) Position Paper on Use of
    Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an
    Emerging
    Virus*
    September
    2017 https://www.who.int/bloodproducts/brn/2017_BRN_PositionPaper_ConvalescentPlasma.pdf
    104. Wu P. et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020 //Eurosurveillance. 2020. Т. 25. №.3. doi:
    10.2807/1560-7917.ES.2020.25.3.2000044 105. Xiao A., et al J Clin Pharm. 2016; 56(1): 56-66; Luzelena Caro, David P. Nicolau, Jan J. De Waele et al.
    Lung penetration, bronchopulmonary pharmacokinetic/ pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of
    Antimicrobial Chemotherapy, dkaa049, https://doi.org/10.1093/jac/dkaa049 Published: 24 March 2020 106. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435. Epub 2020 Mar 30. Review.
    PubMed PMID: 32170806 107. Yuan M. et al. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS ONE. 2020;15:e0230548. doi:10.1371/journal.pone.0230548.
    108. Zhang J. et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet
    Respir Med 2020. doi:10.1016/S2213-2600(20)30071-0.
    109. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China: J Med Virol 2020. doi:10.1002/jmv.25707.
    110. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S.
    The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019
    (COVID-19): The experience of clinical immunologists from China.
    111. Zhang W. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020
    Mar 25;214:108393. doi: 10.1016/j.clim.2020.108393. [Epub ahead of print]
    112. Zumla A. et al. Coronaviruses - drug discovery and therapeutic options // Nature reviews. Drug discovery.
    2016. 15. № 5. С. 327–347.
    113. Всемирная организация здравоохранения. Временное руководство по рациональному использованию средств индивидуальной защиты от коронавирусной болезни (COVID-19)
    и соображения применительно к ситуации их острой нехватки. 6 апреля 2020 г. URL: https://apps.who.int/iris/bitstream/handle/10665/331695/WHO-2019-nCov-IPC_PPE_use-2020.3- rus.pdf
    114. Всемирная организация здравоохранения. Клиническое руководство по ведению пациентов с тяжелыми острыми респираторными инфекциями при подозрении на инфицирование БВРС-КоВ.
    Временные рекомендации. Дата публикации: Июль 2015 г.
    URL: https://www.who.int/csr/disease/coronavirus_infections/case-management-ipc/ru/
    115. Кузьменков А.Ю., Трушин И.В., Авраменко А.А., Эйдельштейн М.В., Дехнич А.В., Козлов Р.С.
    AMRmap: Интернет-платформа мониторинга антибиотикорезистентности. Клиническая микробиология и антимикробная химиотерапия. 2017;19(2):84-90.
    116. Левшин Н.Ю., Баранов А.А., Аршинов А.В. Низкомолекулярный гепарин второго поколения: эффективность, безопасность, мотивация приоритетного применения в клинической практике.
    Трудный пациент. 2014. - № 6. С. 7-14 117. Лучевая диагностика коронавирусной болезни (COVID-19): организация, методология, интерпретация результатов : препринт № ЦДТ – 2020 – I. Версия 2 от 17.04.2020 / сост. С. П.
    Морозов, Д. Н. Проценко, С. В. Сметанина [и др.] // Серия «Лучшие практики лучевой и инструментальной диагностики». – Вып. 65. – М. : ГБУЗ «НПКЦ ДиТ ДЗМ», 2020. – 78 с.
    118. Материалы анализа телеконсультаций НМИЦ ФПИ Минздрава России.
    119. Митьков В.В., и соавт. Консенсусное заявление РАСУДМ об ультразвуковом исследовании легких в условиях COVID-19 (версия 1) // Ультразвуковая и функциональная диагностика. 2020.
    № 1. С. 24–45. Doi: 10.24835/1607-0771-2020-1-24-45. Опубликовано до печати. Режим доступа: // http://www.rasudm.org/files/RASUDM-Consensus-Statement-COVID.pdf, свободный. Загл. с экрана.
    16.04.2020.
    120. Портал непрерывного медицинского и фармацевтического образования Минздрава России URL: https://nmfo
    -vo.edu.rosminzdrav.ru/#/user-account/view-iom/e8b1f2ca-6be5-9125-4a1e
    121. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека.
    Методические рекомендации МР 3.1.0140-18 «Неспецифическая профилактика гриппа и других острых респираторных инфекций».
    122. Христенко Е.А. и соавт. КТ-паттерны при COVID-19 ассоциированных пневмониях – стандартизация описаний исследований на основе глоссария общества Флейшнера // REJR. 2020.
    Т. 10. № 1. С. 16–26.

    161
    Версия 13.1 (09.11.2021)
    123. Синицын В.Е., Тюрин И.Е., Митьков В.В. Временные согласительные методические рекомендации Российского общества рентгенологов и радиологов (РОРР) и Российской ассоциации специалистов ультразвуковой диагностики в медицине (РАСУДМ) «Методы лучевой диагностики пневмонии при новой коронавирусной инфекции COVID-19» (версия 2). Вестник рентгенологии и радиологии. 2020; 101 (2): 72–89. https://doi.org/10.20862/0042-4676-2020-101-2-
    124. Приказ Министерства здравоохранения Российской Федерации от 29 декабря 2012 г. № 1705н "О Порядке организации медицинской реабилитации".
    125. Julie K. Silver: Prehabilitation could save lives in a pandemic March 19, 2020 126. Robert Simpson et al. Rehabilitation Following Critical Illness in People With COVID-19 Infection Am
    J Phys Med Rehabil2020 Apr 10. doi: 10.1097/PHM.0000000000001443.Online ahead of print
    127. Thomas P et al. Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations, Journal of Physiotherapy (2020), doi: https://doi.org/10.1016/j.jphys.2020.03.011.
    128. Kress, J.P. and J.B. Hall, ICU-acquired weakness and recovery from critical illness. N Engl J Med, 2014.
    370(17): p. 1626-35.
    129. Белкин А.А. и соавт. Реабилитация в интенсивной терапии. Клинические рекомендации, 2017, 56 с.
    130. David C et al. Postacute Care Preparedness for COVID-19Thinking Ahead Author Affiliations Article
    Information JAMA. Published online March 25, 2020. doi:10.1001/jama.2020.4686 131. Michele Vitacca et al. Joint statement on the role of respiratory rehabilitation in the COVID-19 crisis: the
    Italian position paper Version - March 08, 2020. Graphics and publishing AIPO Ricerche Ed. - Milano edizioni@aiporicerche.it
    132. Вертикализация пациентов в процессе реабилитации. Клинические рекомендации. Москва,
    2014, 63 с.
    133. Medrinal C et al. Comparison of exercise intensity during four early rehabilitation techniques in sedated and ventilated patients in ICU: A randomised cross-over trial. Crit Care. 2018; 22 (1):110.
    134. Karatzanos E et al. Electrical muscle stimulation: An effective form of exercise and early mobilization to preserve muscle strength in critically ill patients. Crit Care Res Pract. 2012; 2012: 432752.
    135. Fossat G et al. Effect of in-bed leg cycling and electrical stimulation of the quadriceps on global muscle strength in critically ill adults: A Randomized Clinical Trial. JAMA. 2018; 320 (4): 368–378.
    136. Henk J Stam et al. Covid-19 and Post Intensive Care Syndrome: A Call for Action. J Rehabil Med 2020
    Apr 15;52(4):jrm00044 doi: 10.2340/16501977-2677.
    137. Заболотских И.Б. и соавт. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии им. А.И. Салтанова. 2020; S1:9–120. https://doi.org/10.21320/1818-474X-2020-S1-9-120 138. Bein T et al. S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders Revision. Anaesthesist. 2015;64(September):1-26. doi:10.1007/s00101-015-0071-1.
    139. Taito S et al. Early mobilization of mechanically ventilated patients in the intensive care unit. J Intensive
    Care. 2016;4(1):50. doi:10.1186/s40560-016-0179-7.
    140. Eggmann S et al. Physiological effects and safety of an early, combined endurance and resistance training in mechanically ventilated, critically ill patients. Physiotherapy. 2015;101:e344-e345. doi:10.1016/j.physio.2015.03.553 141. Оленская Т.Л. и соавт. Реабилитация в пульмонологии. Учебно-методическое пособие. – Витебск,
    2016. – с. 90-104.
    142. Yang Feng et al. Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV). Cite as Chin J TubercRespir Dis. 2020: 43 (03): 180-182. DOI:
    10.3760/cma.j.issn.1001-0939.2020.03.007.
    143. Robert Simpson et al. Rehabilitation Following Critical Illness in People With COVID-19 Infection Am
    J Phys Med Rehabil2020 Apr 10. doi: 10.1097/PHM.0000000000001443.Online ahead of print
    144. Spruit MA et al. An official american thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J RespirCrit Care Med. 2013;188(8):e13–64.
    145. Насонов ЕЛ и др.; по поручению президиума Общероссийской общественной организации
    «Ассоциация ревматологов России». Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Доступно по ссылке: https://rheumatolog.ru

    162
    Версия 13.1 (09.11.2021)
    146. Schulze-Koops H, et al. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-
    2/Covid-19 pandemic. Ann Rheum Dis. 2020 Apr 28. pii: annrheumdis-2020-217628. doi:
    10.1136/annrheumdis-2020-217628 147. Ceribelli A, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020 May; 109:102442. doi: 10.1016/j.jaut.2020.102442 148. Mikuls TR, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the
    COVID-19 pandemic.
    Arthritis
    Rheumatol doi: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41301.
    149. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone diseases.
    NICE guideline, published 3 april 2020. www.nice.org./uk/guidancr/ng167 150. Kimberly Showalter, et al. Advice on Treating Rheumatic Diseases From a COVID-19 Epicenter -
    Medscape - May 11, 2020.
    151. COVID-19: guidance for rheumatologists.
    British
    Society of
    Rheumatology. htpps//www.rheumatology.org.uk
    152. Кузьков В.В., Киров М.Ю. Инвазивный мониторинг гемодинамики в интенсивной терапии и анестезиологии. Архангельск, 2015. — 392 с.
    153. MR Mehra, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of
    COVID-19: a multinational registry analysis,Lancet, 2020 154. Favipiravir versus
    Arbidol for
    COVID-19:
    A
    Randomized
    Clinical
    Trial. https://doi.org/10.1101/2020.03.17.20037432 155. Furuta Y, et al. : Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad
    Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
    156. Q. Cai, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,
    Engineering (2020), doi: https://doi.org/10.1016/j.eng.2020.03.007 157. Патологическая анатомия COVID-19: Атлас / Зайратьянц О. В., Cамсонова М. В., Михалева Л. М.,
    Черняев А. Л., Мишнев О. Д., Крупнов Н. М., Калинин Д. В. Под общей ред. О. В. Зайратьянца. –
    Москва, ГБУ «НИИОЗММ ДЗМ», 2020. – 140 с., ил.
    158. M.Ackermann, S. Verleden, M.Kuehnel, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and
    Angiogenesis in Covid-19 DOI: 10.1056/NEJMoa2015432 159. S.E. Fox, A. Akmatbekov, J.L Harbert, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020 doi:10.1016/S2213-2600(20)30244-7 160. P.Masi, G.Hékimian, M.Lejeune, et al. Systemic Inflammatory Response Syndrome is a Major
    Contributor to COVID-19-Associated Coagulopathy: Insights from a Prospective Single- Center Cohort
    Study. DOI: 10.1161/CIRCULATIONAHA.120.048925 161. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–47.
    162. Thachil J., Wada H., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; DOI:10.1111/jth.14810.
    163. Spyropoulos A.C., Levy J.H., Ageno W., et al. Scientific and Standardization Committee
    Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous
    Thromboembolism in Hospitalized Patients with COVID-19. J Thromb Haemost 2020; DOI:
    10.1111/jth.14929.
    164. Moores L.K., Tritschler T., Brosnahan S., et al. Prevention, Diagnosis, and Treatment of VTE in Patients
    With COVID-19. CHEST Guideline and Expert Panel Report. Chest 2020; DOI:
    10.1016/j.chest.2020.05.559.
    165. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
    National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/
    166. Вашукова М.А, Цинзерлинг В.А., Семенова Н.Ю., Луговская Н.А., Наркевич Т.А., Суханова Ю.В.
    Возможна ли перинатальная COVID 19: первые результаты. Журнал инфектологии.2020;3 (12):51-
    55.
    167. Дондурей Е.А., Исанкина Л.Н., Афанасьева О.И., Титева А.В., Вишневская Т.В., Кондратьев В.А. и др. Характеристика COVID-19 у детей: первый опыт работы в стационаре Санкт-Петербурга.
    Журнал инфектологии.2020;3 (12):56-63.
    168. Лобзин Ю.В., Черкашина И.В., Самойлова И.Г. Медицинская реабилитация детей, перенесших
    COVID -19. Журнал инфектологии.2020;3 (12):64-74.

    163
    Версия 13.1 (09.11.2021)
    169. Пшенисов К.В., Александрович Ю.С., Казиахмедов В.А., Костик М.М., Кондрашов И.А. Новая коронавирусная инфекция у детей с сопутствующими заболеваниями: шанс на выздоровление есть всегда (клинические случаи) Журнал инфектологии. 2020; 3 (12):80-89.
    170. Усков А.Н, Лобзин Ю.В., Рычкова С.В., Бабаченко И.В., Федоров В.В., Улуханова Л.У.,
    Починяева Л.М. Течение новой коронавирусной инфекции у детей: некоторые аспекты мониторинга и анализа летальности. Журнал инфектологии. 2020; 3 (12):12-21.
    171. Т.А. Руженцова, П.В. Чухляев, Д.А. Хавкина, А.А. и др. Возможности этиотропной терапии коронавирусной инфекции, вызванной SARS-CoV-2, у амбулаторных пациентов. Медицинский оппонент, №1(9), 2020: с. 48-58.
    172. Beigel J.H. et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final
    Report. N Engl J Med. 2020 Oct 8: NEJMoa2007764. doi: 10.1056/NEJMoa2007764.
    173. ESMO guidelines Cancer patients’ management during the COVID-19 pandemic. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic
    174. Kuderer N.M. Chouein T.K., Shah D.P. et al. Clinical impact of COVID-19 jn patients with cancer
    (CCC19): A COHORT STUDY. Lncet 2020; S0140-6736(20)31187-9. Doi; 10.1016.S0140-
    6736(20)311197-9.
    175. Poortmans H.M., Gardoso M.J. Cancer and COVID-19: what do we really know? www.thelancet.com.2020. https: //doi.org/10.1016/S0140-6736(20)31240-X.
    176. Практические рекомендации Российского общества клинической онкологии по оказанию онкологической помощи в условиях пандемии COVID-19. https://rosoncoweb.ru/standarts/COVID-
    19/
    177. Особенности ведения онкогематологических больных в условиях пандемии COVID-19/ Под ред.
    И.В. Поддубной. М.: Экон-Информ, 2020.
    178. Е.А. Борях, О.Л. Кочнева, Е.Н. Мисюрина и соавт. Ведение онкогематологических больных с новой коронавирусной инфекцией: опыт Городской клинической больницы №52. Современная онкология. 2020. Том 22. №2, с. 28-32.
    179. Каприн А.Д., Гамеева Е.В., Поляков А.А. и соавт. Влияние пандемии COVID-19 на онкологическую практику.
    Сибирский онкологический журнал.
    2020;19(3):5-22. https://doi.org/10.21294/1814-4861-2020-19-3-5-22.
    180. Бомштейн Н.Г., Болотов Ю.В., Ким И.А., Д. В. Трухин Д.В. Эффективность сорбированных пробиотиков в комплексном лечении новой коронавирусной инфекции COVID-19 в условиях стационара. Медицина экстремальных ситуаций. 2020; 4 (22):31–35. DOI: 10.4 183/mes.2020.021 181. Захаренко С.М., c соавт. Нежелательные лекарственные реакции со стороны ЖКТ и антибиотикоассоциированная диарея при применении антибиотиков в амбулаторной практике: профилактика и лечение. Клиническая микробиология и антимикробная химиотерапия, 2019; 3:
    196-206.
    182. Guarner F., e.a. World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics.
    February
    2017.
    Available at: http://www.worldgastroenterology.org/guidelines/global- guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english.
    183. Szajewska H., e.a. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr
    Gastroenterol Nutr. 2016; 62(3): 495-506.
    184. Shen N.T., e. a. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection:
    A Systematic Review With MetaRegression Analysis. Gastroenterology. 2017; 152(8): 1889-1900. doi:
    10.1053/j.gastro.2017.02.003.
    185. Зелтынь-Абрамов Е.М. и соавт. Стресс-индуцированная кардиомиопатия у пациентки с фульминантным течением COVID-19 в ранние сроки после аллотрансплантации почки
    (Наблюдение из практики и краткий обзор литературы). Клиническая нефрология. 2020; (2): 10-
    15 DOI: https://dx.doi.org/10.18565/nephrology.2020.2.10-15.
    186. Фролова Н.Ф. и соавт. Новая коронавирусная инфекция COVID-19 у пациентки после аллотрансплантации почки.
    Клиническая нефрология.
    2020;
    2:16-20
    DOI: https://dx.doi.org/10.18565/nephrology.2020.2.16-20.
    187. Зелтынь-Абрамов Е.М. и соавт. COVID19 - ассоциированные поражения сердца у пациентов на программном гемодиализе (Серия клинических наблюдений и краткий обзор литературы).
    Нефрология и диализ. 2020; 22:9-20 DOI: 10.28996/2618-9801-2020-Special_Issue-21-32.
    188. Баутин А.Е., Авдеев С.Н., Сейлиев А.А., Швечкова М.В., Мержоева З.М., Трушенко Н.В., Семенов
    А.П., Лапшин К.Б., Розенберг О.А. Ингаляционная терапия сурфактантом в комплексном лечении

    164
    Версия 13.1 (09.11.2021) тяжелой формы COVID-19-пневмонии. Туберкулёз и болезни лёгких 2020; 98(№9): 6-12. http://doi.org/10.21292/2075-1230-2020-98-9-6-12.
    189. Аверьянов А.В, Клыпа Т.В., Балионис О.И., Бычинин М.В., Черняк А.В., Троицкий А.В.
    Ингаляционный сурфактант при высокопоточной кислородотерапии у больных COVID-19: результаты ретроспективного анализа. Ремедиум 2020; (7-8): doi: 10.21518/1561-5936-2020-7-8-84-
    88.
    190. Piva S, DiBlasi RM, Slee AE, Jobe AH, Roccaro AM, Filippini M, Latronico N, Bertoni M, Marshall
    JC, Portman MA. Surfactant therapy for COVID‑19 related ARDS: a retrospective case–control pilot study. Respir Res 2021; 22: 20. https://doi.org/10.1186/s12931-020-01603-w.
    191. Busani S, Dall’Ara L, Tonelli R, et al. Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia. Ther Adv Respir Dis 2020, 14: 1–6 DOI:
    10.1177/1753466620951043.
    192. Heching M, Lev S, Shitenberg D, Dicker D, Kramer MR, Surfactant for Treatment of ARDS in COVID-
    19 Patient. Chest 2021: doi: https://doi.org/10.1016/j.chest.2021.01.028.
    193. Зелтынь-Абрамов Е.М. и соавт. Факторы риска неблагоприятного прогноза у пациентов на программном гемодиализе с COVID-19. Акцент на сердечно-сосудистую коморбидность (Опыт одного центра). Нефрология и диализ. 2020. 22:21-32. DOI: 10.28996/2618-9801-2020-
    Special_Issue-21-32.
    194. Столяревич Е.С., Фролова Н.Ф., Артюхина Л.Ю., Варясин В.В. Поражение почек при COVID-19: клинические и морфологические проявления почечной патологии у пациентов, умерших от COVID-19. Нефрология и диализ. 2020; 22: 46-55. DOI: 10.28996/2618-9801-2020-Special_Issue-
    46-55 195. Фролова Н.Ф. и соавт. Экулизумаб в лечении АНЦА-ассоциированного васкулита, осложненного
    COVID-19. Клинические наблюдения. Нефрология и диализ. 2020; 22:33-45 DOI: 10.28996/2618-
    9801-2020-Special_Issue-33-45 196. Готье С.В. и соавт. Особенности клинического течения коронавирусной инфекции COVID-19 у реципиентов сердца, почки, печени: первые результаты национального многоцентрового наблюдательного исследования
    «РОККОР-реципиент».
    Вестник трансплантологии и искусственных органов. 2020; 22(3):8-17. https://doi.org/10.15825/1995-1191-2020-3-8-17 197. Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Anti-
    SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-
    Dec;12(1):1854149.
    198. Copin R, et al. In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans. bioRxiv 2021.03.10.434834.
    199. Fact sheet for health care providers emergency use authorization (EUA) of casirivimab and imdevimab. https://www.fda.gov/media/143892/download
    200. Ramakrishnan S. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open- label, randomised controlled trial. Lancet Respir Med. 2021 Apr 9:S2213-2600(21)00160-0.
    201. Ly-Mee Yu et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the
    PRINCIPLE trial.
    2021 https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1 202. Parham Sadeghipour et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients
    With COVID-19 Admitted to the Intensive Care Unit. The INSPIRATION Randomized Clinical Trial
    INSPIRATION Investigators JAMA. 2021;325(16):1620-1630. doi:10.1001/jama.2021.4152 203. Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report The REMAP-
    CAP, ACTIV-4a, and ATTACC Investigators doi:10.1101/2021.03.10.21252749

    165
    Версия 13.1 (09.11.2021)
    1   ...   14   15   16   17   18   19   20   21   ...   26


    написать администратору сайта